“We look forward to partnering with Caidya’s management team and existing investors to support the company’s continued growth plans as a leading global CRO,” said Glaccum. “As both investors and operators in the global healthcare and pharmaceutical services industries, we are excited to bring our expertise to support Caidya’s mission to advance the future of healthcare by providing patients around the world with access to novel therapies.”